Objective: To identify temporal trends in outpatient antibiotic use and antibiotic prescribing practice among older adults.
Introduction
In the US, high rates of antibiotic prescribing pose a major challenge to public health. 1, 2 Clinically inappropriate antibiotic prescribing comprises a large fraction of overall use and contributes to increasingly broad antibiotic resistance. 3 Despite guidelines and calls by federal agencies, professional medical societies, and other organizations to reduce antibiotic prescribing for inappropriate indications, 4 prescribing patterns have changed little. [5] [6] [7] Furthermore, data on antibiotic prescribing trends that can guide stewardship efforts remain sparse, particularly for key vulnerable populations, such as older adults.
Older adults are a particularly important population with respect to antibiotic overuse. They use approximately 50% more antibiotics per capita than younger adults 8 and have the highest risk of poor outcomes from the adverse effects of antibiotics, including Clostridium difficile infection. 9 After several decades of steady antibiotic use, [10] [11] [12] during which use of individual drugs has varied, 11, 13, 14 overall antibiotic use has begun to decline. 4, [15] [16] [17] Recent trends in antibiotic use among older adults, however, are unclear, perhaps having hit a peak in 2006 and a trough in 2014. 18, 19 Furthermore, there is limited data on trends for individual antibiotics and on use of individual antibiotics in association with specific indications. More definitive evidence on antibiotic use and its appropriateness in older adults is needed to guide stewardship interventions in this critical population.
To address this gap, we investigated recent trends in antibiotic prescribing among older adults, using administrative claims from the Medicare program, which provides healthcare insurance for most Americans over 65 years old, from 2011-2015. We focused specifically on trends in potentially inappropriate antibiotic use and heterogeneity in trends among individual antibiotics to identify potential targets for future stewardship interventions.
Methods

Study population
We studied a 20% sample of beneficiaries enrolled in Medicare outpatient medical insurance (Part B) and prescription coverage (Part D) for 2011 through 2015. For each data year, we included only individuals who were continuously enrolled in fee-for-service Medicare (i.e., no months in Medicare Advantage) for the entire year and who were at least 65 years old.
Demographic and clinical variables
To characterize the differences in antibiotic use among older adults, we captured beneficiary sex, race/ethnicity, age, US Census region, eligibility for Medicaid ("dual eligibility"), and the presence of 20 chronic conditions (see Appendix).
Classifying antibiotic claims
We examined original (i.e., not refill) outpatient prescription pharmacy claims for oral and injected antibiotics (Appendix Table 1 ) as defined using the Medicare Formulary file and aggregated by generic antibiotic formulation (Appendix Table 2 ). We excluded refills because we did not expect them to have associated prescriber encounters. We treated multiple claims from the same beneficiary on the same day for the same generic antibiotic as a single claim. To determine how individual antibiotics contributed to overall use and trends, we examined both overall antibiotic claims and claims for each of the 10 most frequently prescribed antibiotics.
Medicare Part D claims data do not include information about antibiotics dispensed in inpatient facilities such as hospitals or skilled nursing facilities.
Encounters and diagnoses
We linked antibiotic claims with outpatient prescriber encounters (Carrier and Outpatient files) and inpatient encounters (Inpatient and Skilled Nursing Facility files). An antibiotic claim was linked with an outpatient encounter if the prescription claim occurred on the day of the encounter or up to 7 days after. A claim was linked with an inpatient encounter if the claim was on the discharge date or up to 7 days after.
Diagnosis codes recorded for these encounters were grouped into 20 diagnostic categories (e.g., pneumonia) using a previously published classification scheme from a US Centers for Disease
Control and Prevention workgroup, described in Fleming-Dutra et al. 2 (We did not follow the exception listed in the "Bronchitis, bronchiolitis" category, "Excludes visits in which the 2nd or 3rd diagnosis was chronic bronchitis, emphysema, or COPD", because this exception was specific to the coding format in their data source.
20
) We also followed that study's organization of diagnostic categories into three antibiotic-appropriateness tiers: Tier 1 ("antibiotics almost always indicated"), Tier 2 ("antibiotics may be indicated"), and Tier 3 ("antibiotics not indicated"). 
Outcomes
To assess trends in antibiotic use, the outcome of interest was the number of antibiotic claims per 1,000 beneficiaries in each year. We considered total antibiotic claims, appropriate claims, inappropriate claims, claims without associated diagnoses, and claims for each of the 10 frequently prescribed antibiotics. Because claims in the fourth quarter of 2015 were not linked to diagnoses, rates of appropriate claims, inappropriate claims, and claims without associated diagnoses were projected from the first three quarters to the full year (by dividing by 0.75) for 2015 only.
To assess the contribution of individual diagnoses to these trends, the outcome of interest was the number of claims for a particular drug linked with a particular diagnosis (e.g., number of azithromycin claims associated with a pneumonia diagnosis) per 1,000 beneficiaries in a year.
We considered the 13 diagnosis categories with the most associated antibiotic claims, grouped those diagnosis categories into 4 infection sites, and considered the 3 antibiotics contributing the most claims for each infection site (see Appendix).
Statistical analyses
To assess trends in the study population characteristics, we performed Poisson regressions (number of beneficiaries, mean age, mean number of chronic conditions) or log-binomial regressions (proportion female, white, dual eligible, and in each Census region) predicting the population characteristic from study year. Adjusted trends in antibiotic use (i.e., claims per beneficiary per year) were assessed using Poisson regression. The main covariate of interest was a linear term for year. We adjusted for beneficiary age, sex (male or female), race (white, black, Hispanic, other), Census region, dual eligibility, and number of chronic conditions. For regressions involving appropriate claims, inappropriate claims, and claims without diagnoses, the period of exposure for each of 2011-2014 was 1 year and for 2015 was 9 months (i.e., excluding
October-December during which ICD-10 was in use), and an offset term was included. When reporting a trend in use, the coefficient for year was projected to the full 2011-2015 span for all regressions. Regressions were performed using PROC GENMOD in SAS (version 9.4).
Clustered standard error estimators accounting for correlations between multiple measurements from the same beneficiaries 21 yielded similar confidence intervals.
Results
Our study sample included 4.6 million unique beneficiaries with 19.8 million antibiotic claims from 2011-2015 (Table 1) . Population characteristics changed by less than 10% over the study period except for the number of beneficiaries and proportion of beneficiaries eligible for Medicaid (Appendix Table 3 ).
Use of all antibiotics fell from 1,362. Table 2 ). Use of amoxicillin/clavulanate, which increased overall, also increased in association with each of these respiratory diagnoses, except pneumonia, for which we did not detect a trend.
In contrast, use of azithromycin, which decreased overall, decreased in association with each of these appropriate and inappropriate diagnostic categories.
For example, use of azithromycin following pneumonia diagnoses, for which antibiotics are considered appropriate, fell from 17. Table 5 ). Use of ciprofloxacin, which fell overall, also fell in association with both infections and other conditions, while use of levofloxacin, which rose overall, also rose in association with both infections and other conditions. Use of metronidazole, which decreased overall (5.1%, 95% CI 4.3-5.8, p < 0.001), fell in association with infections, but we did not detect a trend in use of metronidazole associated with other gastrointestinal conditions.
Prescribing practice for genitourinary and skin/cutaneous/mucosal conditions also largely displayed the pattern of increases or decreases by antibiotic across indications, regardless of appropriateness (Appendix Table 6 , Appendix Table 7) .
Discussion
In this analysis of a national sample of Medicare beneficiaries from 2011 to 2015, we found that overall antibiotic use declined a modest 0.2% and overall inappropriate prescribing declined 4.2%. There was increased use of levofloxacin over azithromycin for all respiratory conditions during this period, whether antibiotics were appropriate for that indication or not. Prescribing practice for other conditions displayed similar patterns, suggesting that changes in antibiotic prescribing practice may be due to shifting preferences for antibiotics across indications rather than targeted reductions in use of particular antibiotics for particular indications. Furthermore, the proportion of antibiotic use we observed as inappropriate (approximately 40%) was substantially higher than previously reported 2 (18% for ³65 years old), indicating that inappropriate antibiotic prescribing among Medicare beneficiaries may be much higher than expected.
There are at least four explanations for the trends we observed in the use of individual antibiotics. Our results are inconsistent with the first two but consistent with the second two. American Thoracic Society issued a recommendation that a respiratory fluoroquinolone be used instead of a macrolide for treating community-acquired pneumonia in certain patients. 22 If this recommendation were still in the process of being implemented during 2011-2015, it could help explain why azithromycin use for pneumonia decreased 18% while use of levofloxacin for pneumonia increased 25% (Table 3) . Second, the trends could reflect concerns about antibiotic resistance, such as rising macrolide resistance among community-acquired pneumonia, 23 which could also explain decreased use of azithromycin for pneumonia. Third, the trends could reflect safety concerns about particular antibiotics. For example, in 2013 the US Food and Drug
Administration warned prescribers that azithromycin might increase the risk of cardiovascular death, 24 which may have contributed to the decreased popularity of azithromycin across diagnoses. Fourth, these trends might represent market factors, such as pricing, availability, and advertising, as suggested in a previous study 12 that found that broad-spectrum antibiotics became more used for both antibiotic-appropriate and antibiotic-inappropriate respiratory indications during 1995-2002.
The first two of these explanations, guidelines and concerns about antibiotic resistance, should be specific to particular antibiotics and diagnoses, while the latter two, safety and market factors, should apply to antibiotics across diagnoses. In this study, we found that use of azithromycin for all respiratory conditions fell, while use of levofloxacin for those conditions rose. This pattern is inconsistent with diagnosis-specific explanations, suggesting that the observed trends in drug use are driven more by safety concerns or market factors than by altered guidelines or by concerns about antibiotic resistance. Furthermore, the slow decline in overall antibiotic use we observed, coupled with the fast trends in use of individual drugs, suggests it is easier to substitute one antibiotic for another than to reduce overall antibiotic use. 25, 26 Our study has several limitations. First, the fee-for-service service beneficiaries for which we have more complete prescription and encounter data may not be representative of the entire US older adult population. 27 Second, pharmacy claims data do not contain information about the condition the drug is intended to treat, so our matching of encounters and prescriptions may have measurement bias or be affected by trends in coding practice. 28, 29 In addition, we were not able to classify approximately 18% of antibiotic claims as appropriate or inappropriate because they had no associated diagnoses, similar to a previous study 30 that found that 15% of Medicare antibiotic claims had no associated encounter. Third, the 5-year period of our study prevents assessment of longer term trends. As a final caveat, we note that the difference between the inappropriate prescribing proportion in this study (40%) and in a previous report 2 demonstrate the challenges in quantifying inappropriate antibiotic use and the need for definitions of appropriate antibiotic use that can be applied across data sources.
In conclusion, we find that overall antibiotic use and inappropriate antibiotic prescribing decreased modestly in a national population of older adults from 2011 to 2015. For drugs used to treat respiratory infections, most changes in antibiotic use were due to increased use of one antibiotic over another across indications, not clinically-oriented changes in use. Changes in antibiotic prescribing practice reflected shifting use between antibiotics rather than declining inappropriate prescribing across antibiotics. Thus, despite decades of effort, appropriateness of nationwide antibiotic use is improving at most incrementally. Bridging the large gap between our goals and past performance will require strong, national policy changes and innovative approaches to stewardship.
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